Literature DB >> 20357818

HGF-promoted motility in primary human melanocytes depends on CD44v6 regulated via NF-kappa B, Egr-1, and C/EBP-beta.

Sabine Damm1, Petra Koefinger, Martina Stefan, Christian Wels, Gabor Mehes, Erika Richtig, Helmut Kerl, Marcus Otte, Helmut Schaider.   

Abstract

The regulation of CD44v6, a variant of the CD44 family of glycosylated adhesion molecules, through hepatocyte growth factor (HGF) has implications for motility in primary human melanocytes. We show that exposure of primary human melanocytes to HGF results in an increase of CD44v6 expression. Immunostaining of melanocytic lesions revealed low cytoplasmic positivity of CD44v6 in some nevi but high membranous expression in primary cutaneous melanomas, and cutaneous and lymph node metastases. HGF-dependent CD44v6 regulation in melanocytes is NF-kappaB dependent because BAY 11-7082, an inhibitor of NF-kappaB activation, but not interference with the mitogen-activated protein kinase or phosphatidylinositol 3-kinase cascade, antagonized HGF-induced CD44v6 expression. NF-kappaB-mediated transcriptional regulation of CD44v6 involves the transcription factors Egr-1 and CCAAT enhancer-binding protein-beta (C/EBP-beta). In gel shift assays, the initial binding of p100/p52 NF-kappaB, C/EBP-beta, and Egr-1 to the CD44 promoter experienced reshuffling toward increased affinity of C/EBP-beta after HGF stimulation. A blocking antibody to CD44v6 decreased HGF-induced c-Met phosphorylation as well as enhanced random- and site-directed migration. Our data show that HGF-induced motility in primary human melanocytes depends on c-Met-CD44v6 interaction, and that HGF-enhanced CD44v6 expression is required for motility and transcriptional upregulation of CD44v6, presumably mediated through a complex comprising NF-kappaB/C/EBP-beta and Egr-1.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20357818      PMCID: PMC2989942          DOI: 10.1038/jid.2010.45

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  44 in total

Review 1.  Met, metastasis, motility and more.

Authors:  Carmen Birchmeier; Walter Birchmeier; Ermanno Gherardi; George F Vande Woude
Journal:  Nat Rev Mol Cell Biol       Date:  2003-12       Impact factor: 94.444

2.  Essential role of HGF (hepatocyte growth factor) in blood formation in Xenopus.

Authors:  Nobutaka Koibuchi; Yasufumi Kaneda; Yoshiaki Taniyama; Kunio Matsumoto; Toshikazu Nakamura; Toshio Ogihara; Ryuichi Morishita
Journal:  Blood       Date:  2003-12-30       Impact factor: 22.113

3.  Hepatocyte growth factor/scatter factor induces feedback up-regulation of CD44v6 in melanoma cells through Egr-1.

Authors:  Juan A Recio; Glenn Merlino
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

4.  Up-regulation of MET expression by alpha-melanocyte-stimulating hormone and MITF allows hepatocyte growth factor to protect melanocytes and melanoma cells from apoptosis.

Authors:  Laurent Beuret; Enrica Flori; Christophe Denoyelle; Karine Bille; Roser Busca; Mauro Picardo; Corine Bertolotto; Robert Ballotti
Journal:  J Biol Chem       Date:  2007-03-19       Impact factor: 5.157

5.  Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment.

Authors:  F Meier; S Busch; K Lasithiotakis; D Kulms; C Garbe; E Maczey; M Herlyn; B Schittek
Journal:  Br J Dermatol       Date:  2007-03-28       Impact factor: 9.302

6.  A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells.

Authors:  U Günthert; M Hofmann; W Rudy; S Reber; M Zöller; I Haussmann; S Matzku; A Wenzel; H Ponta; P Herrlich
Journal:  Cell       Date:  1991-04-05       Impact factor: 41.582

7.  Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product.

Authors:  D P Bottaro; J S Rubin; D L Faletto; A M Chan; T E Kmiecik; G F Vande Woude; S A Aaronson
Journal:  Science       Date:  1991-02-15       Impact factor: 47.728

8.  Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells.

Authors:  R Halaban; J S Rubin; Y Funasaka; M Cobb; T Boulton; D Faletto; E Rosen; A Chan; K Yoko; W White
Journal:  Oncogene       Date:  1992-11       Impact factor: 9.867

9.  Specific interaction of Egr1 and c/EBPbeta leads to the transcriptional activation of the human low density lipoprotein receptor gene.

Authors:  Fang Zhang; Meihong Lin; Parveen Abidi; Gerald Thiel; Jingwen Liu
Journal:  J Biol Chem       Date:  2003-08-28       Impact factor: 5.157

10.  E-cadherin negatively regulates CD44-hyaluronan interaction and CD44-mediated tumor invasion and branching morphogenesis.

Authors:  Yin Xu; Qin Yu
Journal:  J Biol Chem       Date:  2003-01-02       Impact factor: 5.157

View more
  25 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44.

Authors:  Chandi Charan Mandal; Nayana Ghosh-Choudhury; Toshi Yoneda; Goutam Ghosh Choudhury; Nandini Ghosh-Choudhury
Journal:  J Biol Chem       Date:  2011-01-03       Impact factor: 5.157

3.  EGR1 and the ERK-ERF axis drive mammary cell migration in response to EGF.

Authors:  Gabi Tarcic; Roi Avraham; Gur Pines; Ido Amit; Tal Shay; Yiling Lu; Yaara Zwang; Menachem Katz; Nir Ben-Chetrit; Jasmine Jacob-Hirsch; Laura Virgilio; Gideon Rechavi; George Mavrothalassitis; Gordon B Mills; Eytan Domany; Yosef Yarden
Journal:  FASEB J       Date:  2011-12-23       Impact factor: 5.191

4.  Aryl hydrocarbon receptor activation in hematopoietic stem/progenitor cells alters cell function and pathway-specific gene modulation reflecting changes in cellular trafficking and migration.

Authors:  Fanny L Casado; Kameshwar P Singh; Thomas A Gasiewicz
Journal:  Mol Pharmacol       Date:  2011-07-26       Impact factor: 4.436

5.  Intratumoral heterogeneity of CD44v6 in rectal cancer.

Authors:  H-G Liu; L Lv; H Shen
Journal:  Clin Transl Oncol       Date:  2016-08-23       Impact factor: 3.405

6.  Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells.

Authors:  Lin Lv; Hai-Guang Liu; Si-Yang Dong; Fan Yang; Qing-Xuan Wang; Gui-Long Guo; Yi-Fei Pan; Xiao-Hua Zhang
Journal:  Tumour Biol       Date:  2016-01-09

7.  Plexin B1 inhibits MET through direct association and regulates Shp2 expression in melanocytes.

Authors:  Joanne Soong; Glynis Scott
Journal:  J Cell Sci       Date:  2012-11-30       Impact factor: 5.285

8.  p130Cas acts as survival factor during PMA-induced apoptosis in HL-60 promyelocytic leukemia cells.

Authors:  Joerg Kumbrink; Kathrin H Kirsch
Journal:  Int J Biochem Cell Biol       Date:  2012-12-31       Impact factor: 5.085

9.  Isothiocyanate analogs targeting CD44 receptor as an effective strategy against colon cancer.

Authors:  Suniti Misra; Shibnath Ghatak; Alok Vyas; Paul O'Brien; Roger R Markwald; Madhukar Khetmalas; Vincent C Hascall; James B McCarthy; Nikos K Karamanos; Markku I Tammi; Raija H Tammi; Glenn D Prestwitch; Subhash Padhye
Journal:  Med Chem Res       Date:  2014-08-01       Impact factor: 1.965

10.  Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer.

Authors:  Bakhtiyor Yakubov; Bhadrani Chelladurai; Jordan Schmitt; Robert Emerson; John J Turchi; Daniela Matei
Journal:  Neoplasia       Date:  2013-06       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.